RECORDATI
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 1926-01-01
- Employees
- 501
- Market Cap
- $12B
- Website
- https://www.recordati.com.tr
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 72
- Registration Number
- NCT05928390
- Locations
- 🇺🇸
Stanford University School of Medicine, Endocrinology, 800 Welch Road,, Palo Alto, California, United States
🇺🇸Georgia Clinical Research, LLC, 2878 Five Forks Trickum SW, Suite 2A, Lawrenceville, Georgia, United States
🇺🇸Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
- Conditions
- Cushing's Syndrome
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 103
- Registration Number
- NCT05633953
- Locations
- 🇫🇷
Hôpital Haut-Lévèque, Pessac, France
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 206
- Registration Number
- NCT05382156
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇫🇷CHU de Grenoble site Nord, Grenoble, France
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 12
- Registration Number
- NCT03708900
- Locations
- 🇺🇸
University of California San Francisco UCSF, San Francisco, California, United States
🇺🇸National Institute of Child Health and Human Development, Bethesda, Maryland, United States
🇧🇪UZ Brussel, Jette, Brussel, Belgium
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 127
- Registration Number
- NCT03606408
- Locations
- 🇺🇸
Emory University School of Medicine G2304 - C2301, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States
Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Drug: placeboDrug: Rec 0/0438 1 mg or Rec 0/0438 2 mg
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 42
- Registration Number
- NCT03482037
- Locations
- 🇫🇷
Department of Urology, Academic hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne Universités, Paris, France
🇫🇷Centre Hospitalier Lyon Sud Unité de Pharmacie Clinique Oncologique (essai clinique) Pavillon Marcel Bérard - Bât. 1G, Pierre-Bénite, France
🇵🇹Recordati Investigative Site, Porto, Portugal
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 152
- Registration Number
- NCT02310269
- Locations
- 🇨🇦
Centre de recherche du CHUM CRCHUM, Montreal, Quebec, Canada
🇨🇦CHUS - Hopital Fleurimont, Sherbrooke, Quebec, Canada
🇨🇦CHUL Centre de recherche du CHU, Quebec, Canada
Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 104
- Registration Number
- NCT02003742
- Locations
- 🇩🇪
Klinikum der Ludwig-Maximilians-universität München, Munich, Germany
🇮🇹Vita e Salute University, Department of Urology, Istituto Scientifico Ospedale San Raffaele, Milan, Italy
🇵🇱Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
- Conditions
- AcromegalyPituitary TumorsEctopic ACTH Secreting (EAS) TumorsMelanoma Negative for bRAFCushing's DiseaseNeuroendocrine TumorsProstate CancerMelanoma Negative for nRASDumping Syndrome
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 337
- Registration Number
- NCT01794793
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States
🇮🇹Milano Investigative Site, Milano, MI, Italy
🇺🇸Ximed Research SC - SOM230B2412, La Jolla, California, United States
Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
- First Posted Date
- 2012-12-31
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 1036
- Registration Number
- NCT01757769
- Locations
- 🇮🇹
Vita e Salute University, Department of Urology, Istituto Scientifico Ospedale San Raffaele, Milan, Italy